Close Menu

NEW YORK ─ Beckman Coulter said on Thursday that it has received Emergency Use Authorization from the US Food and Drug Administration for its Access Interleukin-6 (IL-6) immunoassay.

The Brea, California-based firm, part of Danaher, said the FDA authorized the fully automated assay for the detection of IL-6 levels in serum and plasma to help physicians identify a severe inflammatory response and determine the risk of intubation with mechanical ventilation in COVID-19 patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.